FI81587C - Foerfarande foer framstaellning av farmaceutiskt anvaendbara n6-substituerade deoxiribosanaloger av adenosiner. - Google Patents
Foerfarande foer framstaellning av farmaceutiskt anvaendbara n6-substituerade deoxiribosanaloger av adenosiner. Download PDFInfo
- Publication number
- FI81587C FI81587C FI854153A FI854153A FI81587C FI 81587 C FI81587 C FI 81587C FI 854153 A FI854153 A FI 854153A FI 854153 A FI854153 A FI 854153A FI 81587 C FI81587 C FI 81587C
- Authority
- FI
- Finland
- Prior art keywords
- mmol
- formula
- compound
- deoxy
- adenosine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 94
- 239000000203 mixture Substances 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- -1 benzyloxy, nitro, amino Chemical group 0.000 claims description 17
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 150000003838 adenosines Chemical class 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 4
- 229960005305 adenosine Drugs 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 3
- 125000001589 carboacyl group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 150000003212 purines Chemical class 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 claims 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 49
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 238000004458 analytical method Methods 0.000 description 33
- 239000007787 solid Substances 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 238000012360 testing method Methods 0.000 description 27
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- 239000006260 foam Substances 0.000 description 25
- 239000002904 solvent Substances 0.000 description 20
- 239000007788 liquid Substances 0.000 description 18
- 239000000460 chlorine Substances 0.000 description 17
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 17
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000002287 radioligand Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 150000002431 hydrogen Chemical group 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- XHRJGHCQQPETRH-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(Cl)=C2N=C1 XHRJGHCQQPETRH-KQYNXXCUSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- FSKMJUWPFLDDRS-XTMLTMLVSA-N (2r,3r,4s,5r)-2-[6-(2,3-dihydro-1h-inden-1-ylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3C4=CC=CC=C4CC3)=C2N=C1 FSKMJUWPFLDDRS-XTMLTMLVSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001631457 Cannula Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000028017 Psychotic disease Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 230000000561 anti-psychotic effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- LAXRIKJRXLWOOO-ORXWAGORSA-N (2R,3R,4S,5R)-2-(6-amino-2-cyclopentylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1(CCCC1)C=1N=C(C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C=2N=1)N LAXRIKJRXLWOOO-ORXWAGORSA-N 0.000 description 3
- RXMTUVIKZRXSSM-UHFFFAOYSA-N 2,2-diphenylethanamine Chemical compound C=1C=CC=CC=1C(CN)C1=CC=CC=C1 RXMTUVIKZRXSSM-UHFFFAOYSA-N 0.000 description 3
- 125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 3
- XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
- WDRISBUVHBMJEF-MROZADKFSA-N 5-deoxy-D-ribose Chemical class C[C@@H](O)[C@@H](O)[C@@H](O)C=O WDRISBUVHBMJEF-MROZADKFSA-N 0.000 description 3
- 102000055025 Adenosine deaminases Human genes 0.000 description 3
- 102000009346 Adenosine receptors Human genes 0.000 description 3
- 108050000203 Adenosine receptors Proteins 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical group [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- RIRGCFBBHQEQQH-UVCRECLJSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(1-phenylpropan-2-ylamino)purin-9-yl]oxolane-3,4-diol Chemical compound N=1C=NC=2N([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C=NC=2C=1NC(C)CC1=CC=CC=C1 RIRGCFBBHQEQQH-UVCRECLJSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 150000008266 deoxy sugars Chemical class 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 2
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- DKJLSDXXOAIWNM-IOSLPCCCSA-N (2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-2-ethyl-4-sulfanyloxolan-3-ol Chemical class S[C@@H]1[C@H](O)[C@@H](CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 DKJLSDXXOAIWNM-IOSLPCCCSA-N 0.000 description 1
- CAMWOVOUQLIMCR-HUJIRHDGSA-N (2R,3R,4S,5R)-2-[6-amino-6-(2,3-dihydro-1H-inden-1-yl)-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1(CCC2=CC=CC=C12)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N CAMWOVOUQLIMCR-HUJIRHDGSA-N 0.000 description 1
- GJKHPMAXXLSZRF-XNIJJKJLSA-N (2S,3S,4R,5R)-2-(chloromethyl)-5-[6-(cyclohexylamino)purin-9-yl]oxolane-3,4-diol Chemical compound C1(CCCCC1)NC=1C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CCl)O3)C=2N=CN=1 GJKHPMAXXLSZRF-XNIJJKJLSA-N 0.000 description 1
- CRRWMFRTRHDOFM-UMCMBGNQSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-2-(2,2-diphenylethyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(CC(C=2C=CC=CC=2)C=2C=CC=CC=2)O[C@H](CO)[C@@H](O)[C@H]1O CRRWMFRTRHDOFM-UMCMBGNQSA-N 0.000 description 1
- TUGMXIURLRAWSS-UMCMBGNQSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC(C=3C=CC=CC=3)C=3C=CC=CC=3)=C2N=C1 TUGMXIURLRAWSS-UMCMBGNQSA-N 0.000 description 1
- RCSHGIGOXHEOEJ-FKLNCEEKSA-N (2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)purin-9-yl]-5-methyloxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C2=NC=NC(NCC(C=3C=CC=CC=3)C=3C=CC=CC=3)=C2N=C1 RCSHGIGOXHEOEJ-FKLNCEEKSA-N 0.000 description 1
- MPRRWZCTCVYXJH-BHICVZBTSA-N (2r,3r,4s,5r)-2-[6-(4-bicyclo[2.2.1]heptanylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC34CCC(CC3)C4)=C2N=C1 MPRRWZCTCVYXJH-BHICVZBTSA-N 0.000 description 1
- SZBULDQSDUXAPJ-XNIJJKJLSA-N (2r,3r,4s,5r)-2-[6-(cyclohexylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCCC3)=C2N=C1 SZBULDQSDUXAPJ-XNIJJKJLSA-N 0.000 description 1
- WDTUGELGJHMRRL-PTGPVQHPSA-N (2r,3r,4s,5s)-2-[6-(2,2-diphenylethylamino)purin-9-yl]-5-(methylsulfanylmethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(NCC(C=3C=CC=CC=3)C=3C=CC=CC=3)=C2N=C1 WDTUGELGJHMRRL-PTGPVQHPSA-N 0.000 description 1
- PBEHSPPPDCLCTM-SCFUHWHPSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(2-phenylpropan-2-ylamino)purin-9-yl]oxolane-3,4-diol Chemical compound C=1C=CC=CC=1C(C)(C)NC(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O PBEHSPPPDCLCTM-SCFUHWHPSA-N 0.000 description 1
- BOZPDAHEDOGGOU-GDERYSGFSA-N (2r,3s,4r,5r)-2-methyl-5-[6-(1-phenylpropan-2-ylamino)purin-9-yl]oxolane-3,4-diol Chemical compound N=1C=NC=2N([C@H]3[C@@H]([C@H](O)[C@@H](C)O3)O)C=NC=2C=1NC(C)CC1=CC=CC=C1 BOZPDAHEDOGGOU-GDERYSGFSA-N 0.000 description 1
- ZKIZBXWHVOAQQX-SDBHATRESA-N (2s,3s,4r,5r)-2-(chloromethyl)-5-[6-(cyclopentylamino)purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CCl)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 ZKIZBXWHVOAQQX-SDBHATRESA-N 0.000 description 1
- XCTRQRHFHPLBKD-LUKQQSODSA-N (2s,3s,4r,5r)-2-(methylsulfanylmethyl)-5-[6-(1-phenylpropan-2-ylamino)purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(NC(C)CC=3C=CC=CC=3)=C2N=C1 XCTRQRHFHPLBKD-LUKQQSODSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WDVKQDALOZKDQQ-UHFFFAOYSA-N 1-cyclohexylpurine Chemical compound C1(CCCCC1)N1C=NC2=NC=NC2=C1 WDVKQDALOZKDQQ-UHFFFAOYSA-N 0.000 description 1
- CKSMLKFVXIYQAQ-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-1-yl)-7h-purine Chemical compound C1=C2NC=NC2=NC(C2C3=CC=CC=C3CC2)=N1 CKSMLKFVXIYQAQ-UHFFFAOYSA-N 0.000 description 1
- ZUYKJZQOPXDNOK-UHFFFAOYSA-N 2-(ethylamino)-2-thiophen-2-ylcyclohexan-1-one;hydrochloride Chemical compound Cl.C=1C=CSC=1C1(NCC)CCCCC1=O ZUYKJZQOPXDNOK-UHFFFAOYSA-N 0.000 description 1
- PLCOEWCMZGOFQZ-HRNJKAHLSA-N 2-[(2S,3S,4R,5R)-5-[6-(ethylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]-2-hydroxyacetamide Chemical compound C(C)NC=1C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](C(O)C(=O)N)O3)C=2N=CN=1 PLCOEWCMZGOFQZ-HRNJKAHLSA-N 0.000 description 1
- YREOLPGEVLLKMB-UHFFFAOYSA-N 3-methylpyridin-1-ium-2-amine bromide hydrate Chemical compound O.[Br-].Cc1ccc[nH+]c1N YREOLPGEVLLKMB-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- UVQKLCCJJLUAFS-UHFFFAOYSA-N C1(CCCC1)N1C=NC2=NC=NC2=C1 Chemical compound C1(CCCC1)N1C=NC2=NC=NC2=C1 UVQKLCCJJLUAFS-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010014523 Embolism and thrombosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100032499 Histamine H2 receptor Human genes 0.000 description 1
- 101710175238 Histamine H2 receptor Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 101001077415 Mus musculus Potassium voltage-gated channel subfamily H member 8 Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004185 Penicillin G procaine Substances 0.000 description 1
- 241000218594 Picea pungens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000079527 Ziziphus spina-christi Species 0.000 description 1
- WBAQACAIXULVTH-UHFFFAOYSA-N [Li].CS Chemical compound [Li].CS WBAQACAIXULVTH-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003243 anti-lipolytic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- 229940017687 beta-d-ribose Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- AJCYEUQRBLMJDI-UHFFFAOYSA-N bis(4-nitrophenyl) hydrogen phosphate;hydrate Chemical compound O.C=1C=C([N+]([O-])=O)C=CC=1OP(=O)(O)OC1=CC=C([N+]([O-])=O)C=C1 AJCYEUQRBLMJDI-UHFFFAOYSA-N 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000013289 male long evans rat Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- XOPUORAQCYGJPT-UHFFFAOYSA-N methanesulfonic acid;hydrochloride Chemical compound Cl.CS(O)(=O)=O XOPUORAQCYGJPT-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-M methanethiolate Chemical compound [S-]C LSDPWZHWYPCBBB-UHFFFAOYSA-M 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NVSYANRBXPURRQ-UHFFFAOYSA-N naphthalen-1-ylmethanamine Chemical compound C1=CC=C2C(CN)=CC=CC2=C1 NVSYANRBXPURRQ-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019370 penicillin G procaine Nutrition 0.000 description 1
- 229940056362 penicillin g procaine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003290 ribose derivatives Chemical class 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66523284A | 1984-10-26 | 1984-10-26 | |
| US66523384A | 1984-10-26 | 1984-10-26 | |
| US66521784A | 1984-10-26 | 1984-10-26 | |
| US66523384 | 1984-10-26 | ||
| US66521784 | 1984-10-26 | ||
| US66523284 | 1984-10-26 | ||
| US77231585A | 1985-09-06 | 1985-09-06 | |
| US77231585 | 1985-09-06 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI854153A0 FI854153A0 (fi) | 1985-10-23 |
| FI854153L FI854153L (fi) | 1986-04-27 |
| FI81587B FI81587B (fi) | 1990-07-31 |
| FI81587C true FI81587C (fi) | 1990-11-12 |
Family
ID=27505316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI854153A FI81587C (fi) | 1984-10-26 | 1985-10-23 | Foerfarande foer framstaellning av farmaceutiskt anvaendbara n6-substituerade deoxiribosanaloger av adenosiner. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0181129B1 (en, 2012) |
| KR (1) | KR910002226B1 (en, 2012) |
| CN (1) | CN1013448B (en, 2012) |
| AU (1) | AU575438B2 (en, 2012) |
| CA (1) | CA1260931A (en, 2012) |
| DE (1) | DE3568582D1 (en, 2012) |
| DK (1) | DK488485A (en, 2012) |
| ES (1) | ES8701774A1 (en, 2012) |
| FI (1) | FI81587C (en, 2012) |
| GR (1) | GR852583B (en, 2012) |
| NO (1) | NO165495C (en, 2012) |
| NZ (1) | NZ213971A (en, 2012) |
| PT (1) | PT81373B (en, 2012) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT82580B (pt) * | 1985-05-15 | 1989-01-17 | Wellcome Found | Processo para a preparacao de 2',3'- didesoxinucleosidos e de composicoes farmaceuticas que os contem |
| AU8276187A (en) * | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
| GB2226027B (en) * | 1988-12-13 | 1992-05-20 | Sandoz Ltd | Adenosine derivatives,their production and use |
| JPH0725785B2 (ja) * | 1989-01-11 | 1995-03-22 | 日本臓器製薬株式会社 | アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物 |
| ZA902280B (en) * | 1989-03-29 | 1990-12-28 | Merrell Dow Pharma | Selective adenosine receptor agents |
| ES2095960T3 (es) * | 1990-09-25 | 1997-03-01 | Rhone Poulenc Rorer Int | Compuestos que tienen propiedades antihipertensivas y antiisquemicas. |
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| EP0601322A3 (en) * | 1992-10-27 | 1994-10-12 | Nippon Zoki Pharmaceutical Co | Adenosine deaminase inhibitor. |
| US5589467A (en) * | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| EA000072B1 (ru) * | 1995-11-14 | 1998-06-25 | Фармация Энд Апджон С.П.А. | Бициклическое конденсированное пиримидиновое соединение и его применение в качестве терапевтического агента |
| TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| ATE246701T1 (de) | 1998-06-23 | 2003-08-15 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate |
| JP3619017B2 (ja) | 1998-06-24 | 2005-02-09 | 日本臓器製薬株式会社 | 新規アラビノシルアデニン誘導体 |
| US7157440B2 (en) | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| US7713946B2 (en) | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
| US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| EP1375508A1 (en) * | 2002-06-27 | 2004-01-02 | Aventis Pharma Deutschland GmbH | N6-substituted adenosine analogues and their use as pharmaceutical agents |
| US7265111B2 (en) | 2002-06-27 | 2007-09-04 | Sanofi-Aventis Deutschland Gmbh | Adenosine analogues and their use as pharmaceutical agents |
| EP1590359A2 (en) | 2003-02-03 | 2005-11-02 | CV Therapeutics Inc. | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1545645A1 (de) * | 1965-12-06 | 1969-08-21 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von disubstituierten Adenosin-Derivaten |
| DE1670077C3 (de) * | 1966-05-07 | 1975-04-24 | Boehringer Mannheim Gmbh, 6800 Mannheim | Adenosin-Derivate und Verfahren zu ihrer Herstellung |
| DE2230160A1 (de) * | 1972-06-21 | 1974-01-31 | Merck Patent Gmbh | Adenosinderivat |
| US4373097A (en) * | 1981-04-27 | 1983-02-08 | Bioresearch S.R.L. | Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity |
| DE3587717T2 (de) * | 1984-04-18 | 1994-04-28 | Whitby Research Inc | N-6-thienyl-substituierte Adenosinderivate als herzgefässerweiternde Mittel. |
| US5310731A (en) * | 1984-06-28 | 1994-05-10 | Whitby Research, Inc. | N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents |
| CA1255297A (en) * | 1984-10-26 | 1989-06-06 | Bharat Trivedi | N.sup.6-benzopyrano and benzothiopyrano adenosines |
-
1985
- 1985-10-21 AU AU48888/85A patent/AU575438B2/en not_active Ceased
- 1985-10-23 FI FI854153A patent/FI81587C/fi not_active IP Right Cessation
- 1985-10-24 DK DK488485A patent/DK488485A/da not_active Application Discontinuation
- 1985-10-25 DE DE8585307717T patent/DE3568582D1/de not_active Expired
- 1985-10-25 GR GR852583A patent/GR852583B/el unknown
- 1985-10-25 NZ NZ213971A patent/NZ213971A/en unknown
- 1985-10-25 NO NO854278A patent/NO165495C/no unknown
- 1985-10-25 ES ES548238A patent/ES8701774A1/es not_active Expired
- 1985-10-25 EP EP85307717A patent/EP0181129B1/en not_active Expired
- 1985-10-25 PT PT81373A patent/PT81373B/pt not_active IP Right Cessation
- 1985-10-25 CA CA000493849A patent/CA1260931A/en not_active Expired
- 1985-10-26 KR KR1019850007937A patent/KR910002226B1/ko not_active Expired
- 1985-10-26 CN CN85108658A patent/CN1013448B/zh not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FI854153L (fi) | 1986-04-27 |
| GR852583B (en, 2012) | 1986-02-26 |
| NO165495B (no) | 1990-11-12 |
| EP0181129A3 (en) | 1987-05-13 |
| AU575438B2 (en) | 1988-07-28 |
| PT81373A (en) | 1985-11-01 |
| NO165495C (no) | 1991-02-20 |
| FI81587B (fi) | 1990-07-31 |
| AU4888885A (en) | 1986-05-08 |
| NO854278L (no) | 1986-04-28 |
| EP0181129B1 (en) | 1989-03-08 |
| CA1260931A (en) | 1989-09-26 |
| PT81373B (pt) | 1987-11-11 |
| DE3568582D1 (en) | 1989-04-13 |
| FI854153A0 (fi) | 1985-10-23 |
| NZ213971A (en) | 1988-03-30 |
| ES548238A0 (es) | 1986-12-01 |
| KR860003256A (ko) | 1986-05-21 |
| EP0181129A2 (en) | 1986-05-14 |
| KR910002226B1 (ko) | 1991-04-08 |
| DK488485D0 (da) | 1985-10-24 |
| CN85108658A (zh) | 1986-07-16 |
| DK488485A (da) | 1986-04-27 |
| ES8701774A1 (es) | 1986-12-01 |
| CN1013448B (zh) | 1991-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI81587C (fi) | Foerfarande foer framstaellning av farmaceutiskt anvaendbara n6-substituerade deoxiribosanaloger av adenosiner. | |
| US5773423A (en) | A3 adenosine receptor agonists | |
| AU592728B2 (en) | N6-substituted adenosines | |
| DE69406649T2 (de) | N-alkyl-2-substituierte atp-analoge | |
| Cottam et al. | New adenosine kinase inhibitors with oral antiinflammatory activity: synthesis and biological evaluation | |
| CZ392797A3 (cs) | C-4´-modifikované inhibitory adenosinkisany | |
| HRP20000275A2 (en) | Chemical compounds | |
| FI77666C (fi) | Foerfarande foer framstaellning av farmaceutiskt anvaendbara n6-substituerade adenosiner. | |
| US4657897A (en) | N6 -substituted adenosines for treating pain | |
| EP0179630B1 (en) | N6-acenaphthyl adenosines and analogs thereof | |
| US4663313A (en) | N6 -tricyclic adenosines for treating hypertension | |
| US4683223A (en) | N6 -Benzopyrano-and benzothiopyrano adenosines and methods of use | |
| EP0181128B1 (en) | N6-bicycloadenosines | |
| CA1262898A (en) | 2,n.sup.6-substituted adenosines derivatives and methods of use | |
| US4600707A (en) | Benzothien-3-yl adenosine; benzothien-3-yl adenosine, S-oxide; and benzothien-3-yl, S,S-dioxide adenosine compounds | |
| US4714697A (en) | N6 -bicycloadenosines and methods of use | |
| US4657898A (en) | N6 -substituted adenosines and method of use | |
| EP0183374B1 (en) | N6-dihydroxypropyladenosines | |
| IE912833A1 (en) | Aica riboside analogs | |
| EP0181109A2 (en) | N6-benzopyrano- and benzothiopyrano-adenosines | |
| US4636493A (en) | Benzothien-3-yl adenosine; benzothien-3-yl adenosine, S-oxide; and benzothien-3-yl, S,S-dioxide adenosine compounds | |
| JPS61148194A (ja) | アデノシンのｎ６−置換デオキシリボ−ス同族体 | |
| JPS62228095A (ja) | Ｎ↑６−置換アデノシン | |
| MXPA94000878A (en) | Inhibitors of the adenosin kinase, which include derivatives of lixofurans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: WARNER-LAMBERT COMPANY |